Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20853809 | 1.00 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL6861531 | 0.97 | CXCR4 (0.39) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL9118993 | 0.97 | CXCR4 (0.44) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL948605 | 0.97 | CXCR4 (0.39) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL10316738 | 0.94 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL21974068 | 0.94 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL6320299 | 0.91 | ALDH1A1 (0.44) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL336034 | 0.90 | CXCR4 (0.50) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL2517620 | 0.90 | CXCR4 (0.50) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL7223038 | 0.89 | CXCR4 (0.35) | CXCR4SMN1; SMN2ALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727561-A1 | TREATMENT OF SOLID TUMORS WITH A REGIMEN OF TARGETED RADIONUCLIDE THERAPY AND GENETICALLY ENGINEERED IMMUNE CELL THERAPIES | Wisconsin Alumni Research Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4705315-A1 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | Merck Sharp & Dohme LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4665410-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4634205-A2 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | Merck Sharp & Dohme LLC (US) | 2025-10-22 | — | — | EP | claimed |
| US-12186410-B2 | Bi-dota complex-loaded dendritic polymer nanoparticles | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-01-07 | — | — | US | claimed |
| WO-2024258913-A1 | TREATMENT OF SOLID TUMORS WITH A REGIMEN OF TARGETED RADIONUCLIDE THERAPY AND GENETICALLY ENGINEERED IMMUNE CELL THERAPIES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-12-19 | — | — | WO | claimed |
| WO-2024228936-A1 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-20240299601-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | REGENERON PHARMA (US) | 2024-09-12 | — | — | US | claimed |
| WO-2024173876-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024129479-A2 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | MERCK SHARP & DOHME LLC (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | claimed |
| EP-3487530-B1 | TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION | WISCONSIN ALUMNI RES FOUND (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | claimed |
| US-20220287658-A1 | IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12 | WAYNE STATE UNIVERSITY (US) | 2022-09-15 | — | — | US | claimed |
| EP-4017534-A1 | IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12 | Wayne State University (US) | 2022-06-29 | — | — | EP | claimed |
| EP-3377504-B1 | CYCLAM BASED COMPOUNDS, THEIR CONJUGATES, CO-ORDINATION COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, METHOD OF PREPARATION AND USE THEREOF | UNIV KARLOVA (CZ) | 2020-08-19 | — | — | EP | claimed |
| US-8987244-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2015-03-24 | — | — | US | claimed |
| US-20140113969-A1 | Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2014-04-24 | — | — | US | claimed |
| US-6951890-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORPORATION LIMITED (NZ) | 2005-10-04 | — | — | US | claimed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287658-A1 | IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12 | IL2, IFNG, CD47 | CXCR4 1107/4885SMN1; SMN2 3197/4885ALDH1A1 2084/4885 |
| US-12186410-B2 | Bi-dota complex-loaded dendritic polymer nanoparticles | CD209, CLTB, PDAP1 | CXCR4 492/4885SMN1; SMN2 4656/4885ALDH1A1 4627/4885 |
| US-20240299601-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | LGALS3, CD47, LGALS3BP | CXCR4 1761/4885SMN1; SMN2 4230/4885ALDH1A1 3970/4885 |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | TNNI3, FABP3, TNNT2 | CXCR4 1025/4885SMN1; SMN2 583/4885ALDH1A1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.